{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:39:29Z","timestamp":1787161169227,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,5,23]],"date-time":"2014-05-23T00:00:00Z","timestamp":1400803200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s40273-014-0165-7","type":"journal-article","created":{"date-parts":[[2014,5,22]],"date-time":"2014-05-22T08:22:15Z","timestamp":1400746935000},"page":"775-787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK"],"prefix":"10.1007","volume":"32","author":[{"given":"Alex","family":"Diamantopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Finckh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. K.","family":"Sungher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dejonckheere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,23]]},"reference":[{"issue":"7","key":"165_CR1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/rheumatology\/41.7.793","volume":"41","author":"D Symmons","year":"2002","unstructured":"Symmons D, Turner G, Webb R, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology. 2002;41(7):793\u2013800.","journal-title":"Rheumatology"},{"issue":"9","key":"165_CR2","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2294\u2013300.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"165_CR3","doi-asserted-by":"crossref","first-page":"iii30","DOI":"10.1136\/ard.2008.098038","volume":"67","author":"SE Gabriel","year":"2008","unstructured":"Gabriel SE. Why do people with rheumatoid arthritis still die prematurely? Ann Rheum Dis. 2008;67(Suppl 3):iii30\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"165_CR4","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/rheumatology\/kep252","volume":"48","author":"C Menue","year":"2009","unstructured":"Menue C, Touze E, Ludovic Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50\u00a0years: a systematic review and meta-analysis of cohort studies. Rheumatology. 2009;48(10):1309\u201313.","journal-title":"Rheumatology"},{"key":"165_CR5","unstructured":"National Audit Offices. Services for people with rheumatoid arthritis. The Stationary Office. http:\/\/www.nao.org.uk\/publications\/0809\/services_for_people_with_rheum.aspx . Accessed Nov 2009."},{"issue":"4","key":"165_CR6","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/art.20528","volume":"51","author":"WB Brouwer","year":"2004","unstructured":"Brouwer WB, van Exel NJ, Van de Berg B, et al. Burden of caregiving: evidence of objective burden, subjective burden, and quality of life impacts on informal caregivers of patients with rheumatoid arthritis. Arthritis Rheum. 2004;51(4):570\u20137.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"165_CR7","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/rheumatology\/keh324","volume":"43","author":"E Hallert","year":"2004","unstructured":"Hallert E, Husberg M, Jonsson D, et al. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project). Rheumatology (Oxford). 2004;43(11):1374\u201382.","journal-title":"Rheumatology (Oxford)"},{"key":"165_CR8","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1002\/art.11439","volume":"48","author":"K Michaud","year":"2003","unstructured":"Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,257 patients. Arthritis Rheum. 2003;48:2750\u201362.","journal-title":"Arthritis Rheum"},{"key":"165_CR9","unstructured":"NICE Assessment report. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying anti-rheumatic drugs and after the failure of conventional disease-modifying anti-rheumatic drugs only: systematic review and economic evaluation. Produced by ScHARR, University of Sheffield. August 2013."},{"key":"165_CR10","unstructured":"NICE TA247 Tocilizumab for the treatment of rheumatoid arthritis (rapid review of technology appraisal guidance 198). February 2012."},{"key":"165_CR11","unstructured":"Scottish Medicines Consortium. Re-submission tocilizumab, 20\u00a0mg\/mL, concentrate for solution for infusion (RoActemra\u00ae) SMC No. (774\/12). August 2012."},{"key":"165_CR12","unstructured":"Gabriel S, Drummond M, Maetzel A, et al. OMERACT 6 Economics working group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol. 2003;30:886\u201390."},{"key":"165_CR13","unstructured":"NICE TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. August 2010."},{"issue":"10","key":"165_CR14","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/rheumatology\/kep242","volume":"48","author":"KL Hyrich","year":"2009","unstructured":"Hyrich KL, Deighton C, Watson KD, et al. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology (Oxford). 2009;48(10):1323\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"165_CR15","unstructured":"NICE TA130 Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. October 2007."},{"issue":"4","key":"165_CR16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/art.1780370408","volume":"37","author":"F Wolfe","year":"1994","unstructured":"Wolfe F. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37(4):481\u201394.","journal-title":"Arthritis Rheum"},{"key":"165_CR17","unstructured":"Buckley F. Presentation 2171-ACR 2012, 10\u201314 Nov, Washington D.C., USA. 2012."},{"issue":"9","key":"165_CR18","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54(9):2793\u2013806.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"165_CR19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3899\/jrheum.120447","volume":"40","author":"RM Fleischmann","year":"2013","unstructured":"Fleischmann RM, Halland AM, Brzosko M, et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J Rheumatol. 2013;40(2):113\u201326.","journal-title":"J Rheumatol"},{"issue":"10","key":"165_CR20","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968\u201380.","journal-title":"Arthritis Rheum"},{"issue":"9617","key":"165_CR21","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987\u201397.","journal-title":"Lancet"},{"key":"165_CR22","unstructured":"Stevenson M, Archer R, Tosh J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying anti-rheumatic drugs and after the failure of conventional disease-modifying anti-rheumatic drugs only: systematic review and economic evaluation. National Institute of Clinical Excellence. August 2013."},{"issue":"8","key":"165_CR23","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/ard.2004.027649","volume":"64","author":"A Gulfe","year":"2005","unstructured":"Gulfe A, Geborek P, Saxne T. Response criteria for rheumatoid arthritis in clinical practice: how useful are they? Ann Rheum Dis. 2005;64(8):1186\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"165_CR24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/ard.2010.139774","volume":"70","author":"MM Soliman","year":"2011","unstructured":"Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70(4):583\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"165_CR25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/rheumatology\/keg451","volume":"43","author":"A Brennan","year":"2004","unstructured":"Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford). 2004;43(1):62\u201372.","journal-title":"Rheumatology (Oxford)"},{"key":"165_CR26","doi-asserted-by":"crossref","unstructured":"Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2):CD008794.","DOI":"10.1002\/14651858.CD008794"},{"issue":"12","key":"165_CR27","first-page":"2563","volume":"30","author":"DE Furst","year":"2003","unstructured":"Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30(12):2563\u201371.","journal-title":"J Rheumatol"},{"issue":"12","key":"165_CR28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","volume":"144","author":"JM Kremer","year":"2006","unstructured":"Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144(12):865\u201376.","journal-title":"Ann Intern Med"},{"key":"165_CR29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","volume":"357","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn\u2019s disease. N Engl J Med. 2007;357:228\u201338.","journal-title":"N Engl J Med"},{"issue":"6","key":"165_CR30","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/art.20277","volume":"50","author":"MH Schiff","year":"2004","unstructured":"Schiff MH, DiVittorio G, Tesser J, et al. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six month observations of patients with comorbid conditions. Arthritis Rheum. 2004;50(6):1752\u201360.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"165_CR31","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/art.21734","volume":"54","author":"R Westhovens","year":"2006","unstructured":"Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 2006;54(4):1075\u201386.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"165_CR32","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jval.2011.12.014","volume":"15","author":"MH Alava","year":"2012","unstructured":"Alava MH, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health. 2012;15(3):550\u201361.","journal-title":"Value Health"},{"issue":"16","key":"165_CR33","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jama.1997.03550160053038","volume":"278","author":"J Sisk","year":"1997","unstructured":"Sisk J, Maskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA. 1997;278(16):1333\u20139.","journal-title":"JAMA"},{"issue":"5","key":"165_CR34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","volume":"13","author":"R Ara","year":"2010","unstructured":"Ara R, Brazier J. Populating an economic model with health state utility values: moving towards better practice. Value Health. 2010;13(5):509\u201318.","journal-title":"Value Health"},{"key":"165_CR35","unstructured":"British National Formulary. British National Formulary 63. Retrieved 1 June 2012, from Medicines Complete. 2012. http:\/\/www.medicinescomplete.com ."},{"key":"165_CR36","unstructured":"Electronic Medicines Compendium (eMC). SPC. Retrieved 1 June 2012, from Electronic Medicines Compendium. 2012. http:\/\/www.medicines.org.uk ."},{"key":"165_CR37","doi-asserted-by":"crossref","unstructured":"Barton P, Jobanputra P, Wilson J, et al. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess. 2004;8(11):iii, 1\u201391.","DOI":"10.3310\/hta8110"},{"key":"165_CR38","unstructured":"NHS reference costs 2010\/2011. Department of Health. Publications policy and guidance. Retrieved 1 March 2012, from Department of Health. 2011. http:\/\/www.dh.gov.uk ."},{"issue":"2","key":"165_CR39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/1529-0131(199902)42:2<347::AID-ANR18>3.0.CO;2-P","volume":"42","author":"G Kobelt","year":"1999","unstructured":"Kobelt G, Eberhardt K, J\u00f6nsson L, J\u00f6nsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 1999;42(2):347\u201356.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"165_CR40","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/rheumatology\/keh703","volume":"44","author":"G Kobelt","year":"2005","unstructured":"Kobelt G, Lindgren P, Lindroth Y, et al. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford). 2005;44(9):1169\u201375.","journal-title":"Rheumatology (Oxford)"},{"key":"165_CR41","unstructured":"NICE. Guide to the methods of technology appraisal. April 2013."},{"key":"165_CR42","doi-asserted-by":"crossref","unstructured":"Boggs R, Sengupta N, Ashraf T. Estimating health utility from a physical function assessment in rheumatoid arthritis (RA) patients treated with adalimumab (HUMIRA). Value Health. 2002;5(6):452.","DOI":"10.1016\/S1098-3015(10)61216-8"},{"issue":"7","key":"165_CR43","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/ard.2004.027565","volume":"64","author":"N Bansback","year":"2005","unstructured":"Bansback N, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis. 2005;64(7):995\u20131002.","journal-title":"Ann Rheum Dis"},{"key":"165_CR44","unstructured":"Ducournau P, Kielhorn A, Wintfeld N. Comparison of linear and non-linear utility mapping between HAQ and EQ-5D using pooled data from the tocilizumab trials OPTION and LITHE. Annual Meeting of the British Society of Rheumatology (BSR), Glasgow. 2009; poster 258."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-014-0165-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-014-0165-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-014-0165-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T14:58:53Z","timestamp":1565449133000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-014-0165-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,23]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["165"],"URL":"https:\/\/doi.org\/10.1007\/s40273-014-0165-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,23]]}}}